Recent News

• 02.10.2026 - Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
• 01.06.2026 - Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
• 12.18.2025 - Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
• 12.16.2025 - Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
• 11.26.2025 - Repligen Corporation to Present at Evercore Healthcare Conference

Recent Filings

• 02.05.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 3 Initial statement of beneficial ownership of securities
• 01.06.2026 - 8-K Current report
• 01.06.2026 - EX-99.1 EX-99.1
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 144 Report of proposed sale of securities
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.26.2025 - 4 Statement of changes in beneficial ownership of securities